Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 15/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18480770 | 1.00 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL18490535 | 0.89 | PDE4D (0.57) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL19632932 | 0.89 | ADK (0.54) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL19636420 | 0.89 | ADK (0.54) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL14154369 | 0.87 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL14154291 | 0.87 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL14644371 | 0.87 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL16480592 | 0.87 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL19229275 | 0.87 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 | |
| SCHEMBL15962778 | 0.87 | ADK (0.52) | ADKADORA2AMETTL3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037078-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | COCRYSTAL PHARMA, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037078-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | COCRYSTAL PHARMA, INC. (US) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037078-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | HAVCR2, HCCS, NAMPT | ADK 248/4885ADORA2A 90/4885METTL3 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.